Biomarker: 17beta-HSD type 2

Histology type: endometrial carcinoma

Country: Japan

Region: Sendai

Followed up time :

Subgroup 1 name : positive

Subgroup 1 number: 8

Subgroup 2 name: negative

Subgroup 2 number: 8

Conclusion: These results suggest that in situ abundance of 17beta-HSD type 2 can predict the possible response of patients with endometrial carcinoma to progestogen treatment.

Sample type : tissue

Sample method: immunoreactivity

Expression pattern : in situ abundance

Expression elevation: After completely reviewing the immunostained sections of each lesion, two of the authors (HU and TS) independently divided the cases into the following three groups: ++, more than 50% positive cells; +, 5– 50% positive cells; and –, less than 5% positive cells

Funtion Uniprot: Cyclin which controls both the G1/S and the G2/M transition phases of the cell cycle. Functions through the formation of specific serine/threonine protein kinase holoenzyme complexes with the cyclin-dependent protein kinases CDK1 or CDK2. The cyclin subunit confers the substrate specificity of these complexes and differentially interacts with and activates CDK1 and CDK2 throughout the cell cycle.

UniProt ID: P20248

UniProt Link: https://www.uniprot.org/uniprotkb/P20248/entry

Biological function from UniProt: #Cell cycle #Cell division #Host-virus interaction #Mitosis

Molecular function from UniProt:

Tissue specificity from UniProt: Accumulates steadily during G2 and is abruptly destroyed at mitosis. Not detected during the G1 phase of the cell cycle. It accumulates during the DNA synthesis/S phase and disappears as cells progress into mitosis, between prophase and metaphase (at protein level).

Subcellular UniProt: #Cytoplasm #Nucleus

Alternative name from UniProt:

Recommended name: Cyclin-A2

Gene name from HGNC: CCNA2 (CCN1, CCNA)

HPA class: Cancer-related genes

AlphaFold DB: P20248

AlphaFold Link: https://alphafold.ebi.ac.uk/entry/P20248

HPA link: https://www.proteinatlas.org/ENSG00000145386-CCNA2

Tissue specificity RNA from HPA: Tissue enhanced (bone marrow, lymphoid tissue, retina)

Tissue expression from HPA: Nuclear expression in a varying fraction of cells in most tissues.

Single cell type specificity Cell type enhanced (Erythroid cells, Extravillous trophoblasts, Cytotrophoblasts, Plasma cells)

Immune cell specificity: Immune cell enhanced (T-reg)

Subcellular summary HPA Located in Nucleoplasm, Cytosol (Single cell variability, CCD Protein, CCD Transcript)

Cancer prognostic summary HPA Prognostic marker in renal cancer (unfavorable), pancreatic cancer (unfavorable), liver cancer (unfavorable), lung cancer (unfavorable) and endometrial cancer (unfavorable)

Pathology link: https://www.proteinatlas.org/ENSG00000145386-CCNA2/pathology

Pathology endo: https://www.proteinatlas.org/ENSG00000145386-CCNA2/pathology/endometrial+cancer

OMIM: 123835

OMIM link2: https://www.omim.org/entry/123835

HGNC ID: HGNC:1578

HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1578